Past Presentation

Tribal Diabetes ECHO: Pancreatitis & SGLT2 Inhibitors | October 14, 2021

Date of Presentation: October 14, 2021

Type: Past Presentation  

Audience: Clinical  

Program: Diabetes ECHO Program  

Keywords: #pancreatitis  #sglt2 inhibitors  

Dr. Greenlee, practitioner at Western Slope Endocrinology in Grand Junction, Colorado, reviews the literature around SGLT2 inhibitors and pancreatitis. This review found:

  1. A series of phase 2 and 3 trials did not identify a link between SGLT2 inhibitors and acute pancreatitis.
  2. Although some case and observational studies have shown an association, this association was tenuous and did not establish a causative link.
  3. There are many other causes of pancreatitis commonly seen in patients with diabetes such as high triglycerides, alcohol abuse, and gallstones.
  4. Drug-induced pancreatitis can arise from many different common medications used in treating people with diabetes.

Dr. Greenlee also presents a diagnostic algorithm to help determine the cause of pancreatitis and discusses recent studies that show even acute bouts of pancreatitis, if severe enough, can cause residual damage to beta cells and exocrine function.


Presenter Bio:

Mary Carol Greenlee, MD, FACP, FACE

Mary Carol Greenlee, MD, FACP, FACE, is board-certified in Internal Medicine and Endocrinology, Diabetes and Metabolism and is in private practice at Western Slope Endocrinology in Grand Junction, Colorado. She is currently serving on the Endocrine Society Council after several years on the Society’s Clinical Affairs Core Committee. She has a special interest in care delivery issues and has been actively involved with the collaborative project sponsored by the Endocrine Society to develop tools to assist with the transition from pediatric to adult care for patients with endocrine disorders.

Date added: November 5, 2021

  • Add to myECHO